Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioNotebook: First trial for Bellicum's CAR T cell safety switch; deals, trials, financings

This article was originally published in Scrip

Executive Summary

NCI study uses Bellicum's CAR T cell safety switch; Innocutis licenses Sitavig from BioAlliance; Portola initiates andexanet alfa Phase III; Alcobra enrolls first Phase III patient; Cardium becomes Taxus Cardium; Sangamo prices $100m offering; Alexza completes $45m private placement; and Oxygen raising $52m.

You may also be interested in...



Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval

Excitement around cell therapy has been building in recent years, but companies expect interest to accelerate after Gilead agreed to buy Kite for $11.9bn and Novartis won the first ever CAR-T approval.

Finance Watch: Four New IPOs Hold Steady In First Days Of Trading

Public Company Edition: Xilio, Ventyx, MiNK and Context went public in the US and later traded at or above their initial public offering prices. Also, Sarepta raised $500m and Relay grossed $350m in new offerings, while Oncopeptides, Esperion, Zymergen and Ardelyx reorganized and cut jobs.

Acceleron Investors Want Merck To Pay More, Ask Company To Wait For Better Offer

Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.

Topics

Related Companies

UsernamePublicRestriction

Register

SC024824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel